Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytodyne to appeal lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Xenadrine marketer will appeal class action ruling by San Diego state court May 30 that firm's ads for ephedra-containing Xenadrine RFA-1 are false, deceptive. Judge Ronald Styn ordered firm to pay $12.5 mil. to California consumers because it is "money obtained by means of unlawful practice." Ruling maintains Cytodyne's "before and after" testimonies are misleading, exaggerate individual results. In response, firm states "we believe California's false advertising laws are so lax that they literally permit any business that advertises a product to be sued - even when, as here, the plaintiff's lawyer doesn't have an injured or deceived client." Plaintiff's lawyer Todd Macaluso of San Diego-based Macaluso & Associates reportedly also will represent parents of Steve Bechler in suit against Cytodyne...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel